Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + Trastuzumab Emtansine in HER2+ Advanced Breast Cancer
NCT02924883Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2016
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Trastuzumab Emtansine + Atezolizumab with Trastuzumab Emtansine + Placebo (2 arms). Primary endpoints: Progression-Free Survival at 15 months and Percentage of Participants With Adverse Events at 40 months. Started Sep 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02924883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02924883.